BMY - Bluebird bio up after peer-reviewed publication of ide-cel data in multiple myeloma

The New England Journal of Medicine has published the Phase 2 study results for CAR T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121) developed by bluebird bio ([[BLUE]] +4.4%) and Bristol Myers Squibb’s ([[BMY]] +0.8%) for a certain group of adults with multiple myeloma.The study results were from patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.The KarMMa study evaluating ide-cel, a B-cell maturation antigen (BCMA)-directed CAR T cell immunotherapy, has met its primary endpoint in 128 trial participants with the overall response rate at 73% across all dose levels.The key secondary endpoint of complete response rate stood at 33%, and the safety profile of ide-cel was found to be consistent with known toxicities of CAR T cell therapies irrespective of the dose level. The commonest adverse events were cytopenia and cytokine release syndrome.The

For further details see:

Bluebird bio up after peer-reviewed publication of ide-cel data in multiple myeloma